Literature DB >> 17133484

Engineered measles virus as a novel oncolytic viral therapy system for hepatocellular carcinoma.

Boris Blechacz1, Patrick L Splinter, Suzanne Greiner, Rae Myers, Kah-Whye Peng, Mark J Federspiel, Stephen J Russell, Nicholas F LaRusso.   

Abstract

The oncolytic measles virus Edmonston strain (MV-Edm), a nonpathogenic virus targeting cells expressing abundant CD46, selectively destroys neoplastic tissue. Clinical development of MV-Edm would benefit from noninvasive monitoring strategies to determine the speed and extent of the spread of the virus in treated patients and the location of virus-infected cells. We evaluated recombinant MV-Edm expressing carcinoembryonic antigen (CEA) or the human sodium iodide symporter (hNIS) for oncolytic potential in hepatocellular carcinoma (HCC) and efficiency in tracking viruses in vivo by noninvasive monitoring. CD46 expression in human HCC and primary hepatocytes was assessed by flow cytometry and immunohistochemistry. Infectivity, syncytium formation, and cytotoxicity of recombinant MV-Edm in HCC cell lines were evaluated by fluorescence microscopy, crystal violet staining, and the MTS assay. Transgene expression in HCC cell lines after infection with recombinant MV-Edm in vitro and in vivo was assessed by CEA concentration, 125I-uptake, and 123I-imaging studies. Toxicology studies were performed in Ifnar(KO)xCD46 transgenic mice. The CD46 receptor was highly expressed in HCC compared to nonmalignant hepatic tissue. Recombinant MV-Edm efficiently infected HCC cell lines, resulting in extensive syncytium formation followed by cell death. Transduction of HCC cell lines and subcutaneous HCC xenografts with recombinant MV-Edm resulted in high-level expression of transgenes in vitro and in vivo. MV-Edm was nontoxic in susceptible mice. Intratumoral and intravenous therapy with recombinant MV-Edm resulted in inhibition of tumor growth and prolongation of survival with complete tumor regression in up to one third of animals. In conclusion, engineered MV-Edm may be a potent and novel cancer gene therapy system for HCC. MV-Edm expressing CEA or hNIS elicited oncolytic effects in human HCC cell lines in vitro and in vivo, enabling the spread of the virus to be monitored in a noninvasive manner.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17133484     DOI: 10.1002/hep.21437

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  54 in total

1.  Oncolytic measles virus retargeting by ligand display.

Authors:  Pavlos Msaouel; Ianko D Iankov; Cory Allen; Stephen J Russell; Evanthia Galanis
Journal:  Methods Mol Biol       Date:  2012

Review 2.  The Sodium/Iodide Symporter (NIS): Molecular Physiology and Preclinical and Clinical Applications.

Authors:  Silvia Ravera; Andrea Reyna-Neyra; Giuseppe Ferrandino; L Mario Amzel; Nancy Carrasco
Journal:  Annu Rev Physiol       Date:  2017-02-10       Impact factor: 19.318

3.  Oncolytic gene therapy with recombinant vaccinia strain GLV-2b372 efficiently kills hepatocellular carcinoma.

Authors:  Justin W Ady; Clark Johnsen; Kelly Mojica; Jacqueline Heffner; Damon Love; Amudhan Pugalenthi; Laurence J Belin; Nanhai G Chen; Yong A Yu; Aladar A Szalay; Yuman Fong
Journal:  Surgery       Date:  2015-06-03       Impact factor: 3.982

4.  Armed and targeted measles virus for chemovirotherapy of pancreatic cancer.

Authors:  S Bossow; C Grossardt; A Temme; M F Leber; S Sawall; E P Rieber; R Cattaneo; C von Kalle; G Ungerechts
Journal:  Cancer Gene Ther       Date:  2011-06-24       Impact factor: 5.987

5.  Noninvasive imaging and radiovirotherapy of prostate cancer using an oncolytic measles virus expressing the sodium iodide symporter.

Authors:  Pavlos Msaouel; Ianko D Iankov; Cory Allen; Ileana Aderca; Mark J Federspiel; Donald J Tindall; John C Morris; Michael Koutsilieris; Stephen J Russell; Evanthia Galanis
Journal:  Mol Ther       Date:  2009-09-22       Impact factor: 11.454

6.  Enhanced antitumor effects of an engineered measles virus Edmonston strain expressing the wild-type N, P, L genes on human renal cell carcinoma.

Authors:  Xin Meng; Takafumi Nakamura; Toshihiko Okazaki; Hiroyuki Inoue; Atsushi Takahashi; Shohei Miyamoto; Gaku Sakaguchi; Masatoshi Eto; Seiji Naito; Makoto Takeda; Yusuke Yanagi; Kenzaburo Tani
Journal:  Mol Ther       Date:  2010-01-05       Impact factor: 11.454

7.  Heat shock protein inhibitors increase the efficacy of measles virotherapy.

Authors:  C Liu; C Erlichman; C J McDonald; J N Ingle; P Zollman; I Iankov; S J Russell; E Galanis
Journal:  Gene Ther       Date:  2008-03-20       Impact factor: 5.250

Review 8.  Oncolytic measles virus strains as novel anticancer agents.

Authors:  Pavlos Msaouel; Mateusz Opyrchal; Evidio Domingo Musibay; Evanthia Galanis
Journal:  Expert Opin Biol Ther       Date:  2013-01-06       Impact factor: 4.388

9.  Quantitative molecular imaging of viral therapy for pancreatic cancer using an engineered measles virus expressing the sodium-iodide symporter reporter gene.

Authors:  Stephanie K Carlson; Kelly L Classic; Elizabeth M Hadac; David Dingli; Claire E Bender; Bradley J Kemp; Stephen J Russell
Journal:  AJR Am J Roentgenol       Date:  2009-01       Impact factor: 3.959

10.  Systemically delivered measles virus-infected mesenchymal stem cells can evade host immunity to inhibit liver cancer growth.

Authors:  Hooi-Tin Ong; Mark J Federspiel; Chang M Guo; London Lucien Ooi; Stephen J Russell; Kah-Whye Peng; Kam M Hui
Journal:  J Hepatol       Date:  2013-07-16       Impact factor: 25.083

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.